Gerresheimer AG GRRMF
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Gerresheimer AG provides specialty glass and plastic products to the pharmaceutical and healthcare industry. The firm operates in three segments: plastics and devices, primary packaging glass and advanced technologies. The plastics and devices segment sells products for drug administration, including insulin pens, inhalers, prefillable syringes, and plastic packaging for medications. The primary packaging glass segment produces glass packaging products for drugs and cosmetics, such as injection vials, cartridges, and jars. The advanced technologies segment develops and manufactures intelligent drug delivery systems. Gerresheimer generates the majority of its revenue in Europe, with sales in Germany contributing the largest proportion of any country.
Duesseldorf, NW, 40468, Germany